|Bid||3.2000 x 1000|
|Ask||3.2900 x 1100|
|Day's Range||2.9600 - 3.2700|
|52 Week Range||1.7100 - 8.3000|
|Beta (5Y Monthly)||1.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 08, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for ONVO
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announces that it has successfully advanced its first inflammatory bowel disease (IBD) model to the next step of target discovery and validation for Crohn’s disease. Based on its internal data and scientific results, the company believes that its first IBD mo
The company's licensing agreement with a Swedish company means an infusion of some much-needed cash for Organovo.